CHU de Québec-Université Laval Research Center, Oncology Division, Hôpital Saint-François d'Assise, 10 Rue de l'Espinay, Quebec City, QC, G1L 3L5, Canada; Faculty of Pharmacy, Laval University, Quebec City, QC, G1V 0A6, Canada.
CHU de Québec-Université Laval Research Center, Oncology Division, Hôpital Saint-François d'Assise, 10 Rue de l'Espinay, Quebec City, QC, G1L 3L5, Canada; Faculty of Pharmacy, Laval University, Quebec City, QC, G1V 0A6, Canada.
Eur J Med Chem. 2018 Jul 15;155:681-694. doi: 10.1016/j.ejmech.2018.06.030. Epub 2018 Jun 21.
N-Phenyl ureidobenzenesulfonates (PUB-SOs) are a new class of anticancer agents blocking the cell cycle progression in S-phase, inducing replicative stress and DNA double-strand breaks (DSBs). In this study, we evaluate the effect of modifying the nature and the position of different substituents on ring A of PUB-SOs on the antiproliferative activity, pharmacological activity as well as on calculated physicochemical, pharmacokinetics and drug-likeness properties. Modification of the urea group by an amide group led to new PUB-SO analogs designated as N-phenyl amidobenzenesulfonates (PAB-SOs). The 2-chloroethyl moiety on ring A was also substituted by different alkyl, cycloalkyl and chloroalkyl groups. The new PAB-SOs and PUB-SOs blocking the cell cycle progression in S-phase exhibit antiproliferative activity in the submicromolar to low micromolar range (0.14-27 μM) on four human cancer cell lines, namely HT-1080, HT-29, M21 and MCF7. Moreover, selected PUB-SO and PAB-SO derivatives induced the phosphorylation of H2AX in M21 cells and do not exhibit or only slightly alkylating activity as confirmed by the 4-(4-nitrobenzyl)pyridine (NBP) assay. Finally, our results show that structure modifications weakly affect the calculated physicochemical, pharmacokinetics and drug-likeness properties of PAB-SOs and PUB-SOs. Therefore, PAB-SOs and PUB-SOs are promising anticancer agents inducing replicative stress and DNA damage via a mechanism of action unrelated to DNA alkylation.
N-苯脲基苯磺酸盐(PUB-SO)是一类新型的抗癌药物,可阻止 S 期细胞周期进展,诱导复制应激和 DNA 双链断裂(DSB)。在本研究中,我们评估了改变 PUB-SO 中环 A 上不同取代基的性质和位置对其增殖活性、药理活性以及计算得出的物理化学、药代动力学和类药性的影响。通过酰胺基团修饰脲基团,得到了新的 PUB-SO 类似物,命名为 N-苯酰胺基苯磺酸盐(PAB-SO)。环 A 上的 2-氯乙基部分也被不同的烷基、环烷基和氯烷基取代。新的 PAB-SO 和 PUB-SO 能阻断 S 期的细胞周期进展,对四种人类癌细胞系(HT-1080、HT-29、M21 和 MCF7)具有亚微摩尔至低微摩尔范围(0.14-27µM)的增殖抑制活性。此外,选定的 PUB-SO 和 PAB-SO 衍生物在 M21 细胞中诱导 H2AX 的磷酸化,并且如 4-(4-硝基苄基)吡啶(NBP)测定所证实的,它们不表现出或仅表现出轻微的烷化活性。最后,我们的结果表明,结构修饰对 PAB-SO 和 PUB-SO 的计算物理化学、药代动力学和类药性的影响较弱。因此,PAB-SO 和 PUB-SO 是有前途的抗癌药物,通过与 DNA 烷化无关的作用机制诱导复制应激和 DNA 损伤。